Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

152 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Salvage Radical Prostatectomy for Recurrent Prostate Cancer: A Systematic Review (French ccAFU).
Saouli A, Ruffion A, Dariane C, Barret E, Fiard G, Hankard GF, Créhange G, Roubaud G, Beauval JB, Brureau L, Renard-Penna R, Gauthé M, Baboudjian M, Ploussard G, Rouprêt M. Saouli A, et al. Among authors: baboudjian m. Cancers (Basel). 2023 Nov 20;15(22):5485. doi: 10.3390/cancers15225485. Cancers (Basel). 2023. PMID: 38001745 Free PMC article. Review.
Vasectomy and Risk of Prostate Cancer: A Systematic Review and Meta-analysis.
Baboudjian M, Rajwa P, Barret E, Beauval JB, Brureau L, Créhange G, Dariane C, Fiard G, Fromont G, Gauthé M, Mathieu R, Renard-Penna R, Roubaud G, Ruffion A, Sargos P, Rouprêt M, Ploussard G; Prostate Cancer Committee of the Association Française d'Urologie CC-AFU. Baboudjian M, et al. Eur Urol Open Sci. 2022 May 19;41:35-44. doi: 10.1016/j.euros.2022.04.012. eCollection 2022 Jul. Eur Urol Open Sci. 2022. PMID: 35633829 Free PMC article. Review.
Perioperative outcomes after radical prostatectomy: does the surgical approach change the impact of hospital volume? A nationwide analysis.
Baboudjian M, Gondran-Tellier B, Grabia A, Barret E, Beauval JB, Brureau L, Crehange G, Dariane C, Fiard G, Fromont G, Gauthe M, Mathieu R, Renard-Penna R, Roubaud G, Ruffion A, Sargos P, Lequeu CE, Roupret M, Ploussard G. Baboudjian M, et al. Minerva Urol Nephrol. 2022 Oct;74(5):638-640. doi: 10.23736/S2724-6051.22.04886-8. Epub 2022 Mar 11. Minerva Urol Nephrol. 2022. PMID: 35274905 Free article. No abstract available.
[Recent advances in the management of localized high-risk prostate cancer: An update by the Prostate Cancer Committee of the French Association of Urology].
Baboudjian M, Beauval JB, Barret E, Brureau L, Créhange G, Dariane C, Fiard G, Fromont G, Gauthé M, Mathieu R, Renard-Penna R, Roubaud G, Ruffion A, Sargos P, Rouprêt M, Ploussard G; Prostate Cancer Committee of the Association française d’urologie (CC-AFU). Baboudjian M, et al. Prog Urol. 2022 Sep;32(10):623-634. doi: 10.1016/j.purol.2022.04.007. Epub 2022 May 27. Prog Urol. 2022. PMID: 35644728 Review. French.
Grade group 1 prostate cancer on biopsy: are we still missing aggressive disease in the era of image-directed therapy?
Baboudjian M, Roumiguié M, Peltier A, Oderda M, Barret E, Fromont G, Dariane C, Fiard G, Charvet AL, Gondran-Tellier B, Durand-Labrunie C, Campello PV, Roumeguère T, Diamand R, Diana P, Touzani A, Beauval JB, Daniel L, Rouprêt M, Ruffion A, Ploussard G; French Prostate Cancer Committee of the Association Française d’Urologie (CC-AFU). Baboudjian M, et al. World J Urol. 2022 Oct;40(10):2423-2429. doi: 10.1007/s00345-022-04130-z. Epub 2022 Aug 18. World J Urol. 2022. PMID: 35980449
What is the ideal combination therapy in de novo, oligometastatic, castration-sensitive prostate cancer?
Baboudjian M, Roubaud G, Fromont G, Gauthé M, Beauval JB, Barret E, Brureau L, Créhange G, Dariane C, Fiard G, Mathieu R, Ruffion A, Rouprêt M, Renard-Penna R, Sargos P, Ploussard G; Prostate Cancer Committee of the French Association of Urology. Baboudjian M, et al. World J Urol. 2023 Aug;41(8):2033-2041. doi: 10.1007/s00345-022-04239-1. Epub 2022 Dec 9. World J Urol. 2023. PMID: 36484817 Review.
How PET-CT is Changing the Management of Non-metastatic Castration-resistant Prostate Cancer?: Comment la TEP-TDM Peut Modifier la Prise en Charge du Cancer de la Prostate Non Métastatique Résistant à la Castration ?
Baboudjian M, Gauthé M, Barret E, Brureau L, Rocchi P, Créhange G, Dariane C, Fiard G, Fromont G, Beauval JB, Mathieu R, Renard-Penna R, Roubaud G, Ruffion A, Sargos P, Rouprêt M, Ploussard G. Baboudjian M, et al. Prog Urol. 2022 Jun;32(6S1):6S43-6S53. doi: 10.1016/S1166-7087(22)00174-9. Prog Urol. 2022. PMID: 36719646 Review.
Expanding inclusion criteria for active surveillance in intermediate-risk prostate cancer: a machine learning approach.
Baboudjian M, Breda A, Roumeguère T, Uleri A, Roche JB, Touzani A, Lacetera V, Beauval JB, Diamand R, Simone G, Windisch O, Benamran D, Fourcade A, Fiard G, Durand-Labrunie C, Roumiguié M, Sanguedolce F, Oderda M, Barret E, Fromont G, Dariane C, Charvet AL, Gondran-Tellier B, Bastide C, Lechevallier E, Palou J, Ruffion A, Van Der Bergh RCN, Peltier A, Ploussard G. Baboudjian M, et al. World J Urol. 2023 May;41(5):1301-1308. doi: 10.1007/s00345-023-04353-8. Epub 2023 Mar 15. World J Urol. 2023. PMID: 36920491
152 results